Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
16.65
-0.08 (-0.48%)
At close: Mar 28, 2025, 4:00 PM
16.62
-0.03 (-0.19%)
After-hours: Mar 28, 2025, 7:57 PM EDT

Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $427.66 million. The enterprise value is $169.60 million.

Market Cap 427.66M
Enterprise Value 169.60M

Important Dates

The last earnings date was Thursday, March 13, 2025, before market open.

Earnings Date Mar 13, 2025
Ex-Dividend Date n/a

Share Statistics

Tourmaline Bio has 25.69 million shares outstanding. The number of shares has increased by 433.98% in one year.

Current Share Class 25.69M
Shares Outstanding 25.69M
Shares Change (YoY) +433.98%
Shares Change (QoQ) +0.11%
Owned by Insiders (%) 8.43%
Owned by Institutions (%) 66.52%
Float 15.58M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.42
P/TBV Ratio 1.43
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 30.18, with a Debt / Equity ratio of 0.00.

Current Ratio 30.18
Quick Ratio 28.99
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -28.99% and return on invested capital (ROIC) is -22.18%.

Return on Equity (ROE) -28.99%
Return on Assets (ROA) -21.60%
Return on Invested Capital (ROIC) -22.18%
Return on Capital Employed (ROCE) -29.90%
Revenue Per Employee n/a
Profits Per Employee -$989,324
Employee Count 74
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -27.29% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -27.29%
50-Day Moving Average 15.33
200-Day Moving Average 19.11
Relative Strength Index (RSI) 54.54
Average Volume (20 Days) 357,023

Short Selling Information

The latest short interest is 3.41 million, so 13.28% of the outstanding shares have been sold short.

Short Interest 3.41M
Short Previous Month 3.42M
Short % of Shares Out 13.28%
Short % of Float 21.89%
Short Ratio (days to cover) 12.56

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -89.73M
Pretax Income -35.69M
Net Income -73.21M
EBITDA -89.69M
EBIT -89.73M
Earnings Per Share (EPS) -$2.89
Full Income Statement

Balance Sheet

The company has $258.30 million in cash and $244,000 in debt, giving a net cash position of $258.06 million or $10.05 per share.

Cash & Cash Equivalents 258.30M
Total Debt 244,000
Net Cash 258.06M
Net Cash Per Share $10.05
Equity (Book Value) 300.05M
Book Value Per Share 11.71
Working Capital 259.93M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$77.26 million and capital expenditures -$9,000, giving a free cash flow of -$77.27 million.

Operating Cash Flow -77.26M
Capital Expenditures -9,000
Free Cash Flow -77.27M
FCF Per Share -$3.01
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth 1
Payout Ratio n/a
Buyback Yield -433.98%
Shareholder Yield n/a
Earnings Yield -17.12%
FCF Yield -18.07%
Dividend Details

Analyst Forecast

The average price target for Tourmaline Bio is $45.20, which is 171.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target $45.20
Price Target Difference 171.47%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 35.92%
EPS Growth Forecast (5Y) -3.43%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score n/a